ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Core Insights - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and is advancing proprietary ADC technology to improve treatment for hematologic malignancies and solid tumors [3]. Company Overview - ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey [5]. - The company has received FDA accelerated approval and conditional approval from the European Commission for its CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4]. - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy, alongside multiple ADCs in ongoing clinical and preclinical development [4]. Upcoming Events - Ameet Mallik, the CEO of ADC Therapeutics, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 2:00 p.m. ET [1]. - A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 30 days [2].